|
We asked 40 pharma leaders, what's your company's most pressing concern?
| Attracting and retaining talent |
38% |
| Pricing and reimbursement issues |
31% |
| Regulatory issues |
23% |
| Pipeline |
8% |
 |
|
|
|
|
|
|
|
|
24 April, 2012 |
 |
| In this Issue |
A New Agenda for the Emerging Markets
Pharm Exec talks to India's most prominent scientist, Dr R.A. Mashelkar, about setting a new agenda for pharma in emerging markets
Read more... |
2012: Outsourcing: Ways to Recover Lost Margins
Although there is sales growth in exciting new global markets, these markets simply cannot command the high-priced drugs of the past. Granted, the potential exists for significantly increased sales volume over time, but the increased sales will be at a lower price and at lower margins, writes Greg Brandyberry. More... |
Scotland, Independence and Pharma
What does a Scottish vote for independence mean for Big Pharma investment and healthcare funding and delivery in the UK? More... |
Marketers: Think Digital First
According to a recent study, only 9 percent of senior-level marketers think that traditional ad agencies are doing a good job of evolving their capabilities for the digital age. Bill Drummy lays out the case of why a digital-first approach to pharma marketing is dramatically more effective than traditional marketing. More...
|
| Case Study |
Reducing outsourcing costs and cycle-times
 Discover how a biotech saved $600,000 on a Phase II contract, compressed the contracting cycle-time from three months to two weeks, and formed a more constructive and collaborative working relationship with their CRO.
 Download the case study today.
|
|
|
|
|
|
|
